ES2312455T3 - Peptidos y su utilizacion en ensayos para enfermedades cardiovasculares. - Google Patents
Peptidos y su utilizacion en ensayos para enfermedades cardiovasculares. Download PDFInfo
- Publication number
- ES2312455T3 ES2312455T3 ES01949734T ES01949734T ES2312455T3 ES 2312455 T3 ES2312455 T3 ES 2312455T3 ES 01949734 T ES01949734 T ES 01949734T ES 01949734 T ES01949734 T ES 01949734T ES 2312455 T3 ES2312455 T3 ES 2312455T3
- Authority
- ES
- Spain
- Prior art keywords
- baselineskip
- peptide
- peptides
- mda
- autoantibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 74
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 35
- 238000012360 testing method Methods 0.000 title claims description 12
- 208000024172 Cardiovascular disease Diseases 0.000 title description 4
- 108010071584 oxidized low density lipoprotein Proteins 0.000 claims description 27
- 150000001413 amino acids Chemical class 0.000 claims description 10
- 238000003018 immunoassay Methods 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 108010007622 LDL Lipoproteins Proteins 0.000 abstract description 15
- 102000007330 LDL Lipoproteins Human genes 0.000 abstract description 15
- 208000029078 coronary artery disease Diseases 0.000 abstract description 13
- 238000003556 assay Methods 0.000 abstract description 5
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 23
- 229940118019 malondialdehyde Drugs 0.000 description 23
- 239000000427 antigen Substances 0.000 description 22
- 102000036639 antigens Human genes 0.000 description 22
- 108091007433 antigens Proteins 0.000 description 22
- 239000013610 patient sample Substances 0.000 description 9
- 230000003647 oxidation Effects 0.000 description 7
- 238000007254 oxidation reaction Methods 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000015636 Oligopeptides Human genes 0.000 description 5
- 108010038807 Oligopeptides Proteins 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 108091005601 modified peptides Proteins 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- JVJFIQYAHPMBBX-UHFFFAOYSA-N 4-hydroxynonenal Chemical compound CCCCCC(O)C=CC=O JVJFIQYAHPMBBX-UHFFFAOYSA-N 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 206010002383 Angina Pectoris Diseases 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 102000001189 Cyclic Peptides Human genes 0.000 description 2
- 108010069514 Cyclic Peptides Proteins 0.000 description 2
- 206010048554 Endothelial dysfunction Diseases 0.000 description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000008694 endothelial dysfunction Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 201000011461 pre-eclampsia Diseases 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- XHTYQFMRBQUCPX-UHFFFAOYSA-N 1,1,3,3-tetramethoxypropane Chemical compound COC(OC)CC(OC)OC XHTYQFMRBQUCPX-UHFFFAOYSA-N 0.000 description 1
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000006991 Apolipoprotein B-100 Human genes 0.000 description 1
- 108010008150 Apolipoprotein B-100 Proteins 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000014882 Carotid artery disease Diseases 0.000 description 1
- 201000000057 Coronary Stenosis Diseases 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 206010038979 Retroperitoneal fibrosis Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 208000037876 carotid Atherosclerosis Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 238000002586 coronary angiography Methods 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- -1 lysine amines Chemical class 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108020001775 protein parts Proteins 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000000954 titration curve Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0017641.2A GB0017641D0 (en) | 2000-07-18 | 2000-07-18 | Peptides and their use |
| GB0017641 | 2000-07-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2312455T3 true ES2312455T3 (es) | 2009-03-01 |
Family
ID=9895897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES01949734T Expired - Lifetime ES2312455T3 (es) | 2000-07-18 | 2001-07-18 | Peptidos y su utilizacion en ensayos para enfermedades cardiovasculares. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20040091934A1 (enExample) |
| EP (1) | EP1301537B1 (enExample) |
| JP (1) | JP2004504327A (enExample) |
| AT (1) | ATE408626T1 (enExample) |
| AU (1) | AU2001270851A1 (enExample) |
| CA (1) | CA2417789A1 (enExample) |
| DE (1) | DE60135846D1 (enExample) |
| DK (1) | DK1301537T3 (enExample) |
| ES (1) | ES2312455T3 (enExample) |
| GB (1) | GB0017641D0 (enExample) |
| PT (1) | PT1301537E (enExample) |
| WO (1) | WO2002006314A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0103754L (sv) * | 2001-04-05 | 2002-10-06 | Forskarpatent I Syd Ab | Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid |
| US20030105003A1 (en) | 2001-04-05 | 2003-06-05 | Jan Nilsson | Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| EP1438060B1 (en) | 2001-09-28 | 2015-11-11 | Esperion Therapeutics Inc. | Prevention and treatment of restenosis by local administration of drug |
| US8926958B2 (en) | 2004-04-06 | 2015-01-06 | Cedars-Sinai Medical Center | Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein A-I and apolipoprotein A-I milano |
| US7776605B2 (en) * | 2006-10-26 | 2010-08-17 | Abbott Laboratories | Assay for cardiac troponin autoantibodies |
| US20080305512A1 (en) * | 2006-10-26 | 2008-12-11 | Mattingly Phillip G | Assay for cardiac troponin autoantibodies |
| EP2097750A2 (en) * | 2006-10-26 | 2009-09-09 | Abbott Laboratories | Immunoassay of analytes in samples containing endogenous anti-analyte antibodies |
| MX2009006744A (es) * | 2006-12-22 | 2009-06-30 | Abbott Lab | Panel de padecimiento cardiovascular autoinmune y metodos de utilizacion del mismo. |
| JP2014516913A (ja) | 2010-11-12 | 2014-07-17 | シーダース シナイ メディカル センター | 高血圧の治療及び／又は予防のための免疫調節方法及びシステム |
| RU2013126628A (ru) | 2010-11-12 | 2014-12-20 | Седарс-Синаи Медикал Сентер | Иммуномодулирующие способы и системы для лечения и/или предотвращения аневризм |
| JP5857312B2 (ja) * | 2011-08-11 | 2016-02-10 | 積水メディカル株式会社 | 心疾患診断マーカー |
| CN107085025B (zh) * | 2016-02-15 | 2019-09-17 | 太原师范学院 | 一种自组装三层膜电极及其制备方法和用途 |
| US10858422B2 (en) | 2016-05-31 | 2020-12-08 | Abcentra, Llc | Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody |
| JP2019527192A (ja) | 2016-05-31 | 2019-09-26 | カーディオバックス リミテッド ライアビリティ カンパニー | 全身性エリテマトーデスの診断及び治療方法 |
| CN111855986A (zh) * | 2019-04-25 | 2020-10-30 | 常州博闻迪医药股份有限公司 | 联合定量检测五项心脏标志物试剂盒及制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5408038A (en) * | 1991-10-09 | 1995-04-18 | The Scripps Research Institute | Nonnatural apolipoprotein B-100 peptides and apolipoprotein B-100-apolipoprotein A-I fusion peptides |
| GB9609702D0 (en) * | 1996-05-09 | 1996-07-10 | Royal Free Hosp School Med | Anticoagulant peptides |
| GB9705831D0 (en) * | 1997-03-20 | 1997-05-07 | Univ Leicester | Oxidised ldl |
| US6635623B1 (en) * | 1997-06-13 | 2003-10-21 | Baylor College Of Medicine | Lipoproteins as nucleic acid vectors |
| ATE385575T1 (de) * | 1997-06-20 | 2008-02-15 | Leuven Res & Dev | Versuchsanordnungen, antikörper und standards für den nachweis von oxidierten und mda-modifizierten lipoproteinen geringer dichte |
-
2000
- 2000-07-18 GB GBGB0017641.2A patent/GB0017641D0/en not_active Ceased
-
2001
- 2001-07-18 JP JP2002512214A patent/JP2004504327A/ja not_active Withdrawn
- 2001-07-18 ES ES01949734T patent/ES2312455T3/es not_active Expired - Lifetime
- 2001-07-18 AT AT01949734T patent/ATE408626T1/de not_active IP Right Cessation
- 2001-07-18 AU AU2001270851A patent/AU2001270851A1/en not_active Abandoned
- 2001-07-18 PT PT01949734T patent/PT1301537E/pt unknown
- 2001-07-18 EP EP01949734A patent/EP1301537B1/en not_active Expired - Lifetime
- 2001-07-18 WO PCT/GB2001/003212 patent/WO2002006314A2/en not_active Ceased
- 2001-07-18 DK DK01949734T patent/DK1301537T3/da active
- 2001-07-18 DE DE60135846T patent/DE60135846D1/de not_active Expired - Fee Related
- 2001-07-18 CA CA002417789A patent/CA2417789A1/en not_active Abandoned
- 2001-07-18 US US10/333,313 patent/US20040091934A1/en not_active Abandoned
-
2007
- 2007-05-04 US US11/800,148 patent/US20080261234A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002006314A3 (en) | 2002-04-18 |
| AU2001270851A1 (en) | 2002-01-30 |
| JP2004504327A (ja) | 2004-02-12 |
| PT1301537E (pt) | 2008-12-04 |
| DK1301537T3 (da) | 2008-12-08 |
| EP1301537B1 (en) | 2008-09-17 |
| US20040091934A1 (en) | 2004-05-13 |
| WO2002006314A2 (en) | 2002-01-24 |
| EP1301537A2 (en) | 2003-04-16 |
| US20080261234A1 (en) | 2008-10-23 |
| GB0017641D0 (en) | 2000-09-06 |
| DE60135846D1 (de) | 2008-10-30 |
| ATE408626T1 (de) | 2008-10-15 |
| CA2417789A1 (en) | 2002-01-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2312455T3 (es) | Peptidos y su utilizacion en ensayos para enfermedades cardiovasculares. | |
| FI84107B (fi) | Hba1c:s immunologiska bestaemningsfoerfarande som innefattar denaturering. | |
| WO2011012053A1 (zh) | 检测血液抗环瓜氨酸多肽抗体的试纸条及制备方法 | |
| JP4153873B2 (ja) | アルツハイマー危険因子の検出試薬および検出用キットならびにこれらを用いるアルツハイマー危険因子の検出方法 | |
| JPWO1995009363A1 (ja) | 酸化リポタンパク質の測定法およびその用途 | |
| Chen et al. | Studies on epitopes on low-density lipoprotein modified by 4-hydroxynonenal. Biochemical characterization and determination | |
| CN108445215A (zh) | 一种定量检测髓过氧化物酶的试剂盒及制备方法 | |
| CA1341113C (en) | Immunoassay for activator peptides | |
| EP0931094A1 (en) | Methods for determining the presence of brain protein s-100 | |
| JP2001504939A (ja) | プロテインｓの測定のための方法および試薬 | |
| WO1992012429A1 (en) | Highly sensitive assay of tissue factor and kit therefor | |
| US6210906B1 (en) | Specific antibodies to kringle 5 of apo(a) and methods of use therefor | |
| JP4280236B2 (ja) | 生体内の酸化ＬＤＬ−β２−グリコプロテインＩ複合体の測定方法 | |
| JP3742415B2 (ja) | Ｒｂ１遺伝子産物に対する自己抗体を検出するための免疫測定用試薬 | |
| JP4203878B2 (ja) | モノクローナル抗体を用いるヒト血漿型ｐａｆ−ａｈの検出方法 | |
| Sato et al. | Enzyme-linked immunosorbent assay for cholesteryl ester transfer protein in human serum | |
| WO2004074833A1 (ja) | 酸化ｌｄｌ－ｃｒｐ複合体の測定方法及び測定キット | |
| JP2001249128A (ja) | 動脈硬化症またはアルツハイマー病の診断用キット | |
| JPH06279494A (ja) | リポタンパク質（ａ）ペプチドおよびその使用 | |
| JP2000304747A (ja) | 動脈硬化症惹起性リポ蛋白の検出方法およびこれに用いる抗体 | |
| WO2009056826A1 (en) | Diagnostic and therapeutic methods and compositions for cardiovascular disease | |
| Ames | Atherogenesis and Atherosclerosis in Primary Antiphospholipid Syndrome | |
| JP2004286737A (ja) | ｐ１６遺伝子ファミリーに含まれる癌抑制遺伝子の産物に対する自己抗体を検出するための免疫測定用試薬 | |
| JPH10111290A (ja) | ＩｇＡ腎症の診断法 | |
| JPWO1990009587A1 (ja) | ヒト・オステオカルシンの免疫学的測定方法、そのための試薬及びキツト、ヒト・オステオカルシンに対する抗体、それを産生するハイブリドーマ及びそれを産生する方法 |